Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia

IF 2.2 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology Pub Date : 2024-06-14 DOI:10.1111/ijlh.14326

Hui Zeng, Jie He, Hai-Bo Dong, Min Zhou, Qian Zhang, Lan-Xin Chen, Cui-Ying Yuan, Ru-Ru Jiang, Jin-Wen Liu, Jian Ou-Yang, Yu Ben, Bing Chen

{"title":"Negative expression of CD117 predicted inferior OS and PFS in acute promyelocytic leukemia","authors":"Hui Zeng, Jie He, Hai-Bo Dong, Min Zhou, Qian Zhang, Lan-Xin Chen, Cui-Ying Yuan, Ru-Ru Jiang, Jin-Wen Liu, Jian Ou-Yang, Yu Ben, Bing Chen","doi":"10.1111/ijlh.14326","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>In recent years, the correlation between CD117 antigen and the prognosis of hematological malignancies has been demonstrated. However, there is limited literature on the clinical significance of CD117 antigen in acute promyelocytic leukemia (APL). The aim of this study was to retrospectively analyze the clinical features and prognostic significance of CD117 in APL.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this study, we retrospectively investigated the clinicopathological characteristics, outcome, and prognostic impact of negative CD117 expression (CD117<sup>−</sup>) in 169 APL patients treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) containing regimen.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median follow-up period was 63.0 months. CD117<sup>−</sup> was detected in 13 APL patients (7.7%). No significant differences were found in baseline characteristics between CD117+ and CD117<sup>−</sup> subgroups. However, compared to CD117+ APL, the incidence of early death (ED) was significantly higher in CD117<sup>−</sup> APL (<i>p</i> = 0.023). By multivariate analysis, CD117- was an independent adverse prognostic factor for overall survival (OS) and progression-free survival (PFS) (<i>p</i> = 0.022 and <i>p</i> = 0.014, respectively).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>To sum up, CD117<sup>−</sup> is associated with greater risk of ED and has the statistical power to predict inferior OS and PFS, this marker may be considered to build prognostic scores for risk-adapted therapeutic strategies in APL management.</p>\n </section>\n </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"46 6","pages":"1052-1058"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14326","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Laboratory Hematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ijlh.14326","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In recent years, the correlation between CD117 antigen and the prognosis of hematological malignancies has been demonstrated. However, there is limited literature on the clinical significance of CD117 antigen in acute promyelocytic leukemia (APL). The aim of this study was to retrospectively analyze the clinical features and prognostic significance of CD117 in APL.

Methods

In this study, we retrospectively investigated the clinicopathological characteristics, outcome, and prognostic impact of negative CD117 expression (CD117⁻) in 169 APL patients treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) containing regimen.

Results

The median follow-up period was 63.0 months. CD117⁻ was detected in 13 APL patients (7.7%). No significant differences were found in baseline characteristics between CD117+ and CD117⁻ subgroups. However, compared to CD117+ APL, the incidence of early death (ED) was significantly higher in CD117⁻ APL (p = 0.023). By multivariate analysis, CD117- was an independent adverse prognostic factor for overall survival (OS) and progression-free survival (PFS) (p = 0.022 and p = 0.014, respectively).

Conclusions

To sum up, CD117⁻ is associated with greater risk of ED and has the statistical power to predict inferior OS and PFS, this marker may be considered to build prognostic scores for risk-adapted therapeutic strategies in APL management.

Abstract Image

查看原文本刊更多论文

CD117 阴性表达预示急性早幼粒细胞白血病的较差 OS 和 PFS。

引言：近年来，CD117 抗原与血液恶性肿瘤预后的相关性已得到证实。然而，关于 CD117 抗原在急性早幼粒细胞白血病（APL）中的临床意义的文献却很有限。本研究旨在回顾性分析 CD117 在 APL 中的临床特征和预后意义：在这项研究中，我们回顾性调查了169例接受全反式维甲酸（ATRA）和含三氧化二砷（ATO）方案治疗的APL患者的临床病理特征、治疗结果以及CD117阴性表达（CD117-）对预后的影响：中位随访期为 63.0 个月。13例APL患者（7.7%）检测到CD117-。CD117+和CD117-亚组的基线特征无明显差异。然而，与 CD117+ APL 相比，CD117- APL 早期死亡（ED）的发生率明显更高（p = 0.023）。通过多变量分析，CD117-是总生存期（OS）和无进展生存期（PFS）的独立不良预后因素（分别为p = 0.022和p = 0.014）：综上所述，CD117-与更大的ED风险相关，并具有预测较差的OS和PFS的统计学能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Laboratory Hematology 医学-血液学

CiteScore

4.50

自引率

6.70%

发文量

211

审稿时长

6-12 weeks

期刊介绍： The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology. The journal publishes invited reviews, full length original articles, and correspondence. The International Journal of Laboratory Hematology is the official journal of the International Society for Laboratory Hematology, which addresses the following sub-disciplines: cellular analysis, flow cytometry, haemostasis and thrombosis, molecular diagnostics, haematology informatics, haemoglobinopathies, point of care testing, standards and guidelines. The journal was launched in 2006 as the successor to Clinical and Laboratory Hematology, which was first published in 1979. An active and positive editorial policy ensures that work of a high scientific standard is reported, in order to bridge the gap between practical and academic aspects of laboratory haematology.